However, an understanding of the GEFs that activate it to drive metastasis in lung cancer, and the mechanism by which these GEFs are facilitating the activation of Rac1, could provide novel opportunities for the development of lung cancer therapeutics. Here, RAC1 is linked to lung carcinoma.